nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—Fingolimod—multiple sclerosis	0.121	0.246	CbGbCtD
Alfuzosin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0778	0.158	CbGbCtD
Alfuzosin—CYP3A4—Triamcinolone—multiple sclerosis	0.0589	0.12	CbGbCtD
Alfuzosin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0567	0.116	CbGbCtD
Alfuzosin—CYP3A4—Betamethasone—multiple sclerosis	0.0506	0.103	CbGbCtD
Alfuzosin—CYP3A4—Prednisolone—multiple sclerosis	0.0499	0.102	CbGbCtD
Alfuzosin—CYP3A4—Prednisone—multiple sclerosis	0.0471	0.096	CbGbCtD
Alfuzosin—CYP3A4—Dexamethasone—multiple sclerosis	0.0294	0.0599	CbGbCtD
Alfuzosin—Somnolence—Mitoxantrone—multiple sclerosis	0.000879	0.0019	CcSEcCtD
Alfuzosin—Loss of consciousness—Prednisolone—multiple sclerosis	0.000874	0.00189	CcSEcCtD
Alfuzosin—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000871	0.00188	CcSEcCtD
Alfuzosin—Angiopathy—Dexamethasone—multiple sclerosis	0.000865	0.00187	CcSEcCtD
Alfuzosin—Angiopathy—Betamethasone—multiple sclerosis	0.000865	0.00187	CcSEcCtD
Alfuzosin—Fatigue—Mitoxantrone—multiple sclerosis	0.000853	0.00184	CcSEcCtD
Alfuzosin—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000848	0.00183	CcSEcCtD
Alfuzosin—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000846	0.00183	CcSEcCtD
Alfuzosin—Pain—Mitoxantrone—multiple sclerosis	0.000846	0.00183	CcSEcCtD
Alfuzosin—Constipation—Mitoxantrone—multiple sclerosis	0.000846	0.00183	CcSEcCtD
Alfuzosin—Diarrhoea—Azathioprine—multiple sclerosis	0.000837	0.00181	CcSEcCtD
Alfuzosin—Discomfort—Prednisolone—multiple sclerosis	0.000836	0.00181	CcSEcCtD
Alfuzosin—Angioedema—Triamcinolone—multiple sclerosis	0.000835	0.00181	CcSEcCtD
Alfuzosin—Angioedema—Methylprednisolone—multiple sclerosis	0.000833	0.0018	CcSEcCtD
Alfuzosin—Malaise—Triamcinolone—multiple sclerosis	0.000824	0.00178	CcSEcCtD
Alfuzosin—Malaise—Methylprednisolone—multiple sclerosis	0.000823	0.00178	CcSEcCtD
Alfuzosin—Vertigo—Triamcinolone—multiple sclerosis	0.000821	0.00178	CcSEcCtD
Alfuzosin—Syncope—Triamcinolone—multiple sclerosis	0.00082	0.00177	CcSEcCtD
Alfuzosin—Vertigo—Methylprednisolone—multiple sclerosis	0.00082	0.00177	CcSEcCtD
Alfuzosin—Syncope—Methylprednisolone—multiple sclerosis	0.000818	0.00177	CcSEcCtD
Alfuzosin—Connective tissue disorder—Prednisone—multiple sclerosis	0.000815	0.00176	CcSEcCtD
Alfuzosin—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000815	0.00176	CcSEcCtD
Alfuzosin—Oedema—Prednisolone—multiple sclerosis	0.000811	0.00176	CcSEcCtD
Alfuzosin—Dizziness—Azathioprine—multiple sclerosis	0.000809	0.00175	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000809	0.00175	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000805	0.00174	CcSEcCtD
Alfuzosin—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000804	0.00174	CcSEcCtD
Alfuzosin—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000802	0.00173	CcSEcCtD
Alfuzosin—Shock—Prednisolone—multiple sclerosis	0.000798	0.00173	CcSEcCtD
Alfuzosin—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000798	0.00173	CcSEcCtD
Alfuzosin—Tachycardia—Prednisolone—multiple sclerosis	0.000792	0.00171	CcSEcCtD
Alfuzosin—Urticaria—Mitoxantrone—multiple sclerosis	0.000786	0.0017	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000784	0.0017	CcSEcCtD
Alfuzosin—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000782	0.00169	CcSEcCtD
Alfuzosin—Vomiting—Azathioprine—multiple sclerosis	0.000778	0.00168	CcSEcCtD
Alfuzosin—Arthralgia—Methylprednisolone—multiple sclerosis	0.000777	0.00168	CcSEcCtD
Alfuzosin—Eye disorder—Prednisone—multiple sclerosis	0.000776	0.00168	CcSEcCtD
Alfuzosin—Infestation—Methotrexate—multiple sclerosis	0.000773	0.00167	CcSEcCtD
Alfuzosin—Drowsiness—Methotrexate—multiple sclerosis	0.000773	0.00167	CcSEcCtD
Alfuzosin—Infestation NOS—Methotrexate—multiple sclerosis	0.000773	0.00167	CcSEcCtD
Alfuzosin—Rash—Azathioprine—multiple sclerosis	0.000771	0.00167	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000771	0.00167	CcSEcCtD
Alfuzosin—Dermatitis—Azathioprine—multiple sclerosis	0.000771	0.00167	CcSEcCtD
Alfuzosin—Flushing—Prednisone—multiple sclerosis	0.00077	0.00167	CcSEcCtD
Alfuzosin—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00077	0.00166	CcSEcCtD
Alfuzosin—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00077	0.00166	CcSEcCtD
Alfuzosin—Discomfort—Triamcinolone—multiple sclerosis	0.000769	0.00166	CcSEcCtD
Alfuzosin—Discomfort—Methylprednisolone—multiple sclerosis	0.000767	0.00166	CcSEcCtD
Alfuzosin—Headache—Azathioprine—multiple sclerosis	0.000766	0.00166	CcSEcCtD
Alfuzosin—Dry mouth—Triamcinolone—multiple sclerosis	0.000761	0.00165	CcSEcCtD
Alfuzosin—Angioedema—Dexamethasone—multiple sclerosis	0.000758	0.00164	CcSEcCtD
Alfuzosin—Angioedema—Betamethasone—multiple sclerosis	0.000758	0.00164	CcSEcCtD
Alfuzosin—Angiopathy—Prednisone—multiple sclerosis	0.000753	0.00163	CcSEcCtD
Alfuzosin—Malaise—Betamethasone—multiple sclerosis	0.000748	0.00162	CcSEcCtD
Alfuzosin—Malaise—Dexamethasone—multiple sclerosis	0.000748	0.00162	CcSEcCtD
Alfuzosin—Oedema—Triamcinolone—multiple sclerosis	0.000746	0.00161	CcSEcCtD
Alfuzosin—Vertigo—Betamethasone—multiple sclerosis	0.000745	0.00161	CcSEcCtD
Alfuzosin—Vertigo—Dexamethasone—multiple sclerosis	0.000745	0.00161	CcSEcCtD
Alfuzosin—Syncope—Betamethasone—multiple sclerosis	0.000744	0.00161	CcSEcCtD
Alfuzosin—Syncope—Dexamethasone—multiple sclerosis	0.000744	0.00161	CcSEcCtD
Alfuzosin—Infection—Triamcinolone—multiple sclerosis	0.000741	0.0016	CcSEcCtD
Alfuzosin—Sweating—Methotrexate—multiple sclerosis	0.000741	0.0016	CcSEcCtD
Alfuzosin—Infection—Methylprednisolone—multiple sclerosis	0.00074	0.0016	CcSEcCtD
Alfuzosin—Shock—Triamcinolone—multiple sclerosis	0.000734	0.00159	CcSEcCtD
Alfuzosin—Shock—Methylprednisolone—multiple sclerosis	0.000732	0.00158	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000731	0.00158	CcSEcCtD
Alfuzosin—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00073	0.00158	CcSEcCtD
Alfuzosin—Loss of consciousness—Betamethasone—multiple sclerosis	0.000729	0.00158	CcSEcCtD
Alfuzosin—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000729	0.00158	CcSEcCtD
Alfuzosin—Tachycardia—Triamcinolone—multiple sclerosis	0.000728	0.00158	CcSEcCtD
Alfuzosin—Mental disorder—Prednisone—multiple sclerosis	0.000727	0.00157	CcSEcCtD
Alfuzosin—Nausea—Azathioprine—multiple sclerosis	0.000727	0.00157	CcSEcCtD
Alfuzosin—Tachycardia—Methylprednisolone—multiple sclerosis	0.000727	0.00157	CcSEcCtD
Alfuzosin—Skin disorder—Methylprednisolone—multiple sclerosis	0.000723	0.00156	CcSEcCtD
Alfuzosin—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000721	0.00156	CcSEcCtD
Alfuzosin—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00072	0.00156	CcSEcCtD
Alfuzosin—Asthenia—Mitoxantrone—multiple sclerosis	0.00071	0.00153	CcSEcCtD
Alfuzosin—Discomfort—Dexamethasone—multiple sclerosis	0.000698	0.00151	CcSEcCtD
Alfuzosin—Discomfort—Betamethasone—multiple sclerosis	0.000698	0.00151	CcSEcCtD
Alfuzosin—Hypotension—Methylprednisolone—multiple sclerosis	0.000696	0.0015	CcSEcCtD
Alfuzosin—Pain—Prednisolone—multiple sclerosis	0.000694	0.0015	CcSEcCtD
Alfuzosin—Pharyngitis—Methotrexate—multiple sclerosis	0.000688	0.00149	CcSEcCtD
Alfuzosin—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000685	0.00148	CcSEcCtD
Alfuzosin—Urethral disorder—Methotrexate—multiple sclerosis	0.00068	0.00147	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00068	0.00147	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000678	0.00147	CcSEcCtD
Alfuzosin—Oedema—Betamethasone—multiple sclerosis	0.000677	0.00146	CcSEcCtD
Alfuzosin—Oedema—Dexamethasone—multiple sclerosis	0.000677	0.00146	CcSEcCtD
Alfuzosin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000677	0.00146	CcSEcCtD
Alfuzosin—Infection—Dexamethasone—multiple sclerosis	0.000673	0.00145	CcSEcCtD
Alfuzosin—Infection—Betamethasone—multiple sclerosis	0.000673	0.00145	CcSEcCtD
Alfuzosin—Ill-defined disorder—Prednisone—multiple sclerosis	0.00067	0.00145	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisolone—multiple sclerosis	0.000669	0.00145	CcSEcCtD
Alfuzosin—Shock—Dexamethasone—multiple sclerosis	0.000666	0.00144	CcSEcCtD
Alfuzosin—Shock—Betamethasone—multiple sclerosis	0.000666	0.00144	CcSEcCtD
Alfuzosin—Nervous system disorder—Betamethasone—multiple sclerosis	0.000664	0.00144	CcSEcCtD
Alfuzosin—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000664	0.00144	CcSEcCtD
Alfuzosin—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000663	0.00143	CcSEcCtD
Alfuzosin—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000663	0.00143	CcSEcCtD
Alfuzosin—Tachycardia—Betamethasone—multiple sclerosis	0.000661	0.00143	CcSEcCtD
Alfuzosin—Tachycardia—Dexamethasone—multiple sclerosis	0.000661	0.00143	CcSEcCtD
Alfuzosin—Angioedema—Prednisone—multiple sclerosis	0.00066	0.00143	CcSEcCtD
Alfuzosin—Dyspepsia—Triamcinolone—multiple sclerosis	0.000657	0.00142	CcSEcCtD
Alfuzosin—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000655	0.00142	CcSEcCtD
Alfuzosin—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000654	0.00142	CcSEcCtD
Alfuzosin—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000654	0.00142	CcSEcCtD
Alfuzosin—Malaise—Prednisone—multiple sclerosis	0.000651	0.00141	CcSEcCtD
Alfuzosin—Vertigo—Prednisone—multiple sclerosis	0.000649	0.0014	CcSEcCtD
Alfuzosin—Eye disorder—Methotrexate—multiple sclerosis	0.000648	0.0014	CcSEcCtD
Alfuzosin—Syncope—Prednisone—multiple sclerosis	0.000648	0.0014	CcSEcCtD
Alfuzosin—Urticaria—Prednisolone—multiple sclerosis	0.000645	0.00139	CcSEcCtD
Alfuzosin—Cardiac disorder—Methotrexate—multiple sclerosis	0.000644	0.00139	CcSEcCtD
Alfuzosin—Fatigue—Triamcinolone—multiple sclerosis	0.000643	0.00139	CcSEcCtD
Alfuzosin—Fatigue—Methylprednisolone—multiple sclerosis	0.000642	0.00139	CcSEcCtD
Alfuzosin—Pain—Triamcinolone—multiple sclerosis	0.000638	0.00138	CcSEcCtD
Alfuzosin—Loss of consciousness—Prednisone—multiple sclerosis	0.000635	0.00137	CcSEcCtD
Alfuzosin—Hypotension—Betamethasone—multiple sclerosis	0.000633	0.00137	CcSEcCtD
Alfuzosin—Hypotension—Dexamethasone—multiple sclerosis	0.000633	0.00137	CcSEcCtD
Alfuzosin—Angiopathy—Methotrexate—multiple sclerosis	0.000629	0.00136	CcSEcCtD
Alfuzosin—Vomiting—Mitoxantrone—multiple sclerosis	0.000629	0.00136	CcSEcCtD
Alfuzosin—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000625	0.00135	CcSEcCtD
Alfuzosin—Rash—Mitoxantrone—multiple sclerosis	0.000624	0.00135	CcSEcCtD
Alfuzosin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000623	0.00135	CcSEcCtD
Alfuzosin—Headache—Mitoxantrone—multiple sclerosis	0.00062	0.00134	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000617	0.00133	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000617	0.00133	CcSEcCtD
Alfuzosin—Arthralgia—Prednisone—multiple sclerosis	0.000615	0.00133	CcSEcCtD
Alfuzosin—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000615	0.00133	CcSEcCtD
Alfuzosin—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000613	0.00133	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000611	0.00132	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000609	0.00132	CcSEcCtD
Alfuzosin—Discomfort—Prednisone—multiple sclerosis	0.000608	0.00131	CcSEcCtD
Alfuzosin—Mental disorder—Methotrexate—multiple sclerosis	0.000608	0.00131	CcSEcCtD
Alfuzosin—Dyspepsia—Betamethasone—multiple sclerosis	0.000596	0.00129	CcSEcCtD
Alfuzosin—Dyspepsia—Dexamethasone—multiple sclerosis	0.000596	0.00129	CcSEcCtD
Alfuzosin—Urticaria—Triamcinolone—multiple sclerosis	0.000593	0.00128	CcSEcCtD
Alfuzosin—Urticaria—Methylprednisolone—multiple sclerosis	0.000591	0.00128	CcSEcCtD
Alfuzosin—Oedema—Prednisone—multiple sclerosis	0.00059	0.00128	CcSEcCtD
Alfuzosin—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000589	0.00127	CcSEcCtD
Alfuzosin—Nausea—Mitoxantrone—multiple sclerosis	0.000587	0.00127	CcSEcCtD
Alfuzosin—Infection—Prednisone—multiple sclerosis	0.000586	0.00127	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000584	0.00126	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000584	0.00126	CcSEcCtD
Alfuzosin—Back pain—Methotrexate—multiple sclerosis	0.000584	0.00126	CcSEcCtD
Alfuzosin—Fatigue—Betamethasone—multiple sclerosis	0.000584	0.00126	CcSEcCtD
Alfuzosin—Fatigue—Dexamethasone—multiple sclerosis	0.000584	0.00126	CcSEcCtD
Alfuzosin—Shock—Prednisone—multiple sclerosis	0.00058	0.00125	CcSEcCtD
Alfuzosin—Pain—Betamethasone—multiple sclerosis	0.000579	0.00125	CcSEcCtD
Alfuzosin—Pain—Dexamethasone—multiple sclerosis	0.000579	0.00125	CcSEcCtD
Alfuzosin—Nervous system disorder—Prednisone—multiple sclerosis	0.000578	0.00125	CcSEcCtD
Alfuzosin—Tachycardia—Prednisone—multiple sclerosis	0.000575	0.00124	CcSEcCtD
Alfuzosin—Skin disorder—Prednisone—multiple sclerosis	0.000573	0.00124	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisone—multiple sclerosis	0.00057	0.00123	CcSEcCtD
Alfuzosin—Ill-defined disorder—Methotrexate—multiple sclerosis	0.00056	0.00121	CcSEcCtD
Alfuzosin—Feeling abnormal—Betamethasone—multiple sclerosis	0.000558	0.00121	CcSEcCtD
Alfuzosin—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000558	0.00121	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000554	0.0012	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000554	0.0012	CcSEcCtD
Alfuzosin—Malaise—Methotrexate—multiple sclerosis	0.000544	0.00118	CcSEcCtD
Alfuzosin—Vertigo—Methotrexate—multiple sclerosis	0.000542	0.00117	CcSEcCtD
Alfuzosin—Urticaria—Betamethasone—multiple sclerosis	0.000538	0.00116	CcSEcCtD
Alfuzosin—Urticaria—Dexamethasone—multiple sclerosis	0.000538	0.00116	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000537	0.00116	CcSEcCtD
Alfuzosin—Dizziness—Prednisolone—multiple sclerosis	0.000537	0.00116	CcSEcCtD
Alfuzosin—Asthenia—Triamcinolone—multiple sclerosis	0.000535	0.00116	CcSEcCtD
Alfuzosin—Abdominal pain—Dexamethasone—multiple sclerosis	0.000535	0.00116	CcSEcCtD
Alfuzosin—Abdominal pain—Betamethasone—multiple sclerosis	0.000535	0.00116	CcSEcCtD
Alfuzosin—Asthenia—Methylprednisolone—multiple sclerosis	0.000534	0.00116	CcSEcCtD
Alfuzosin—Pruritus—Triamcinolone—multiple sclerosis	0.000528	0.00114	CcSEcCtD
Alfuzosin—Pruritus—Methylprednisolone—multiple sclerosis	0.000527	0.00114	CcSEcCtD
Alfuzosin—Dyspepsia—Prednisone—multiple sclerosis	0.000519	0.00112	CcSEcCtD
Alfuzosin—Arthralgia—Methotrexate—multiple sclerosis	0.000514	0.00111	CcSEcCtD
Alfuzosin—Chest pain—Methotrexate—multiple sclerosis	0.000514	0.00111	CcSEcCtD
Alfuzosin—Rash—Prednisolone—multiple sclerosis	0.000512	0.00111	CcSEcCtD
Alfuzosin—Dermatitis—Prednisolone—multiple sclerosis	0.000511	0.00111	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00051	0.0011	CcSEcCtD
Alfuzosin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000509	0.0011	CcSEcCtD
Alfuzosin—Fatigue—Prednisone—multiple sclerosis	0.000508	0.0011	CcSEcCtD
Alfuzosin—Headache—Prednisolone—multiple sclerosis	0.000508	0.0011	CcSEcCtD
Alfuzosin—Discomfort—Methotrexate—multiple sclerosis	0.000508	0.0011	CcSEcCtD
Alfuzosin—Constipation—Prednisone—multiple sclerosis	0.000504	0.00109	CcSEcCtD
Alfuzosin—Dizziness—Triamcinolone—multiple sclerosis	0.000493	0.00107	CcSEcCtD
Alfuzosin—Dizziness—Methylprednisolone—multiple sclerosis	0.000492	0.00106	CcSEcCtD
Alfuzosin—Infection—Methotrexate—multiple sclerosis	0.00049	0.00106	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisone—multiple sclerosis	0.000486	0.00105	CcSEcCtD
Alfuzosin—Asthenia—Betamethasone—multiple sclerosis	0.000486	0.00105	CcSEcCtD
Alfuzosin—Asthenia—Dexamethasone—multiple sclerosis	0.000486	0.00105	CcSEcCtD
Alfuzosin—Nervous system disorder—Methotrexate—multiple sclerosis	0.000483	0.00105	CcSEcCtD
Alfuzosin—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000482	0.00104	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000482	0.00104	CcSEcCtD
Alfuzosin—Nausea—Prednisolone—multiple sclerosis	0.000482	0.00104	CcSEcCtD
Alfuzosin—Pruritus—Dexamethasone—multiple sclerosis	0.000479	0.00104	CcSEcCtD
Alfuzosin—Pruritus—Betamethasone—multiple sclerosis	0.000479	0.00104	CcSEcCtD
Alfuzosin—Skin disorder—Methotrexate—multiple sclerosis	0.000479	0.00104	CcSEcCtD
Alfuzosin—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000476	0.00103	CcSEcCtD
Alfuzosin—Vomiting—Triamcinolone—multiple sclerosis	0.000474	0.00103	CcSEcCtD
Alfuzosin—Vomiting—Methylprednisolone—multiple sclerosis	0.000473	0.00102	CcSEcCtD
Alfuzosin—Rash—Triamcinolone—multiple sclerosis	0.00047	0.00102	CcSEcCtD
Alfuzosin—Dermatitis—Triamcinolone—multiple sclerosis	0.00047	0.00102	CcSEcCtD
Alfuzosin—Rash—Methylprednisolone—multiple sclerosis	0.000469	0.00102	CcSEcCtD
Alfuzosin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000469	0.00101	CcSEcCtD
Alfuzosin—Urticaria—Prednisone—multiple sclerosis	0.000468	0.00101	CcSEcCtD
Alfuzosin—Headache—Triamcinolone—multiple sclerosis	0.000467	0.00101	CcSEcCtD
Alfuzosin—Headache—Methylprednisolone—multiple sclerosis	0.000466	0.00101	CcSEcCtD
Alfuzosin—Abdominal pain—Prednisone—multiple sclerosis	0.000466	0.00101	CcSEcCtD
Alfuzosin—Diarrhoea—Dexamethasone—multiple sclerosis	0.000463	0.001	CcSEcCtD
Alfuzosin—Diarrhoea—Betamethasone—multiple sclerosis	0.000463	0.001	CcSEcCtD
Alfuzosin—Hypotension—Methotrexate—multiple sclerosis	0.00046	0.000996	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000449	0.000971	CcSEcCtD
Alfuzosin—Dizziness—Dexamethasone—multiple sclerosis	0.000448	0.000968	CcSEcCtD
Alfuzosin—Dizziness—Betamethasone—multiple sclerosis	0.000448	0.000968	CcSEcCtD
Alfuzosin—Nausea—Triamcinolone—multiple sclerosis	0.000443	0.000959	CcSEcCtD
Alfuzosin—Nausea—Methylprednisolone—multiple sclerosis	0.000442	0.000957	CcSEcCtD
Alfuzosin—Somnolence—Methotrexate—multiple sclerosis	0.000438	0.000948	CcSEcCtD
Alfuzosin—Dyspepsia—Methotrexate—multiple sclerosis	0.000434	0.000938	CcSEcCtD
Alfuzosin—Vomiting—Dexamethasone—multiple sclerosis	0.00043	0.000931	CcSEcCtD
Alfuzosin—Vomiting—Betamethasone—multiple sclerosis	0.00043	0.000931	CcSEcCtD
Alfuzosin—Rash—Betamethasone—multiple sclerosis	0.000427	0.000923	CcSEcCtD
Alfuzosin—Rash—Dexamethasone—multiple sclerosis	0.000427	0.000923	CcSEcCtD
Alfuzosin—Dermatitis—Dexamethasone—multiple sclerosis	0.000426	0.000922	CcSEcCtD
Alfuzosin—Dermatitis—Betamethasone—multiple sclerosis	0.000426	0.000922	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000425	0.00092	CcSEcCtD
Alfuzosin—Fatigue—Methotrexate—multiple sclerosis	0.000425	0.000919	CcSEcCtD
Alfuzosin—Headache—Dexamethasone—multiple sclerosis	0.000424	0.000917	CcSEcCtD
Alfuzosin—Headache—Betamethasone—multiple sclerosis	0.000424	0.000917	CcSEcCtD
Alfuzosin—Asthenia—Prednisone—multiple sclerosis	0.000423	0.000915	CcSEcCtD
Alfuzosin—Pain—Methotrexate—multiple sclerosis	0.000421	0.000911	CcSEcCtD
Alfuzosin—Pruritus—Prednisone—multiple sclerosis	0.000417	0.000902	CcSEcCtD
Alfuzosin—Feeling abnormal—Methotrexate—multiple sclerosis	0.000406	0.000878	CcSEcCtD
Alfuzosin—Diarrhoea—Prednisone—multiple sclerosis	0.000403	0.000873	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000403	0.000872	CcSEcCtD
Alfuzosin—Nausea—Dexamethasone—multiple sclerosis	0.000402	0.00087	CcSEcCtD
Alfuzosin—Nausea—Betamethasone—multiple sclerosis	0.000402	0.00087	CcSEcCtD
Alfuzosin—Urticaria—Methotrexate—multiple sclerosis	0.000391	0.000847	CcSEcCtD
Alfuzosin—Dizziness—Prednisone—multiple sclerosis	0.00039	0.000843	CcSEcCtD
Alfuzosin—Abdominal pain—Methotrexate—multiple sclerosis	0.00039	0.000843	CcSEcCtD
Alfuzosin—Vomiting—Prednisone—multiple sclerosis	0.000375	0.000811	CcSEcCtD
Alfuzosin—Rash—Prednisone—multiple sclerosis	0.000372	0.000804	CcSEcCtD
Alfuzosin—Dermatitis—Prednisone—multiple sclerosis	0.000371	0.000803	CcSEcCtD
Alfuzosin—Headache—Prednisone—multiple sclerosis	0.000369	0.000799	CcSEcCtD
Alfuzosin—Asthenia—Methotrexate—multiple sclerosis	0.000354	0.000765	CcSEcCtD
Alfuzosin—Nausea—Prednisone—multiple sclerosis	0.00035	0.000758	CcSEcCtD
Alfuzosin—Pruritus—Methotrexate—multiple sclerosis	0.000349	0.000754	CcSEcCtD
Alfuzosin—Diarrhoea—Methotrexate—multiple sclerosis	0.000337	0.000729	CcSEcCtD
Alfuzosin—Dizziness—Methotrexate—multiple sclerosis	0.000326	0.000705	CcSEcCtD
Alfuzosin—Vomiting—Methotrexate—multiple sclerosis	0.000313	0.000678	CcSEcCtD
Alfuzosin—Rash—Methotrexate—multiple sclerosis	0.000311	0.000672	CcSEcCtD
Alfuzosin—Dermatitis—Methotrexate—multiple sclerosis	0.00031	0.000671	CcSEcCtD
Alfuzosin—Headache—Methotrexate—multiple sclerosis	0.000309	0.000668	CcSEcCtD
Alfuzosin—Nausea—Methotrexate—multiple sclerosis	0.000293	0.000633	CcSEcCtD
Alfuzosin—ADRA1B—GPCR downstream signaling—RGS1—multiple sclerosis	0.000101	0.00217	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CXCL10—multiple sclerosis	0.0001	0.00215	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CCR2—multiple sclerosis	0.0001	0.00215	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	9.89e-05	0.00212	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CCL3—multiple sclerosis	9.84e-05	0.00211	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	9.71e-05	0.00208	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCL13—multiple sclerosis	9.61e-05	0.00206	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—S1PR1—multiple sclerosis	9.61e-05	0.00206	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CCR1—multiple sclerosis	9.61e-05	0.00206	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—GPR65—multiple sclerosis	9.61e-05	0.00206	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	9.58e-05	0.00205	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—PTGER4—multiple sclerosis	9.47e-05	0.00203	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	9.41e-05	0.00202	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CNR1—multiple sclerosis	9.24e-05	0.00198	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—RGS1—multiple sclerosis	9.2e-05	0.00197	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CXCR3—multiple sclerosis	9.15e-05	0.00196	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—RGS1—multiple sclerosis	9e-05	0.00193	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CCR2—multiple sclerosis	8.9e-05	0.00191	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TAGAP—multiple sclerosis	8.81e-05	0.00189	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	8.79e-05	0.00188	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCL13—multiple sclerosis	8.79e-05	0.00188	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CCR1—multiple sclerosis	8.79e-05	0.00188	CbGpPWpGaD
Alfuzosin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.73e-05	0.00187	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—GPR65—multiple sclerosis	8.72e-05	0.00187	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CCL5—multiple sclerosis	8.63e-05	0.00185	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—GPR65—multiple sclerosis	8.53e-05	0.00183	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	8.48e-05	0.00182	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—LINGO1—multiple sclerosis	8.43e-05	0.00181	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	8.41e-05	0.0018	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	8.36e-05	0.00179	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CXCL10—multiple sclerosis	8.32e-05	0.00178	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CNR1—multiple sclerosis	8.21e-05	0.00176	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—RGS1—multiple sclerosis	8.17e-05	0.00175	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	7.98e-05	0.00171	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCL13—multiple sclerosis	7.98e-05	0.00171	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCR1—multiple sclerosis	7.98e-05	0.00171	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	7.95e-05	0.0017	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	7.81e-05	0.00167	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CCR1—multiple sclerosis	7.8e-05	0.00167	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCL13—multiple sclerosis	7.8e-05	0.00167	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CCR5—multiple sclerosis	7.78e-05	0.00167	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—GPR65—multiple sclerosis	7.75e-05	0.00166	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—S1PR1—multiple sclerosis	7.7e-05	0.00165	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	7.53e-05	0.00161	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—LINGO1—multiple sclerosis	7.49e-05	0.0016	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—GPC5—multiple sclerosis	7.49e-05	0.0016	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CXCL10—multiple sclerosis	7.39e-05	0.00158	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TAGAP—multiple sclerosis	7.31e-05	0.00157	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PTGER4—multiple sclerosis	7.26e-05	0.00155	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CCL5—multiple sclerosis	7.17e-05	0.00153	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCL13—multiple sclerosis	7.09e-05	0.00152	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCR1—multiple sclerosis	7.09e-05	0.00152	CbGpPWpGaD
Alfuzosin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.08e-05	0.00152	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	7.06e-05	0.00151	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CXCR3—multiple sclerosis	7.01e-05	0.0015	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—MAPK1—multiple sclerosis	6.88e-05	0.00147	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CCL3—multiple sclerosis	6.85e-05	0.00147	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CCR2—multiple sclerosis	6.82e-05	0.00146	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	6.63e-05	0.00142	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PTGER4—multiple sclerosis	6.59e-05	0.00141	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RGS1—multiple sclerosis	6.55e-05	0.0014	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TAGAP—multiple sclerosis	6.5e-05	0.00139	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	6.48e-05	0.00139	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CCR5—multiple sclerosis	6.46e-05	0.00138	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—S1PR1—multiple sclerosis	6.39e-05	0.00137	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCR3—multiple sclerosis	6.37e-05	0.00136	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CCL5—multiple sclerosis	6.36e-05	0.00136	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CNR1—multiple sclerosis	6.29e-05	0.00135	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GPC5—multiple sclerosis	6.22e-05	0.00133	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—GPR65—multiple sclerosis	6.21e-05	0.00133	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CCR2—multiple sclerosis	6.19e-05	0.00133	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	6.1e-05	0.00131	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—POMC—multiple sclerosis	6.08e-05	0.0013	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PTGER4—multiple sclerosis	6.03e-05	0.00129	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CCL2—multiple sclerosis	5.95e-05	0.00127	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	5.88e-05	0.00126	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCR3—multiple sclerosis	5.82e-05	0.00125	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	5.76e-05	0.00123	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CCR5—multiple sclerosis	5.73e-05	0.00123	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CNR1—multiple sclerosis	5.72e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCL3—multiple sclerosis	5.68e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—S1PR1—multiple sclerosis	5.68e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCR1—multiple sclerosis	5.68e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCL13—multiple sclerosis	5.68e-05	0.00122	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CXCL10—multiple sclerosis	5.67e-05	0.00121	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CCR2—multiple sclerosis	5.66e-05	0.00121	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GPC5—multiple sclerosis	5.52e-05	0.00118	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PTGER4—multiple sclerosis	5.47e-05	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RGS1—multiple sclerosis	5.44e-05	0.00116	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PTGER4—multiple sclerosis	5.35e-05	0.00115	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCR3—multiple sclerosis	5.28e-05	0.00113	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CNR1—multiple sclerosis	5.22e-05	0.00112	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCR3—multiple sclerosis	5.17e-05	0.00111	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—GPR65—multiple sclerosis	5.15e-05	0.0011	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCL10—multiple sclerosis	5.15e-05	0.0011	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCR2—multiple sclerosis	5.14e-05	0.0011	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	5.06e-05	0.00108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCL3—multiple sclerosis	5.05e-05	0.00108	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—POMC—multiple sclerosis	5.05e-05	0.00108	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CCR2—multiple sclerosis	5.03e-05	0.00108	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CCL2—multiple sclerosis	4.94e-05	0.00106	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CCL5—multiple sclerosis	4.88e-05	0.00104	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PTGER4—multiple sclerosis	4.86e-05	0.00104	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RGS1—multiple sclerosis	4.83e-05	0.00103	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CNR1—multiple sclerosis	4.74e-05	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCR1—multiple sclerosis	4.71e-05	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCL13—multiple sclerosis	4.71e-05	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCL10—multiple sclerosis	4.7e-05	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCR3—multiple sclerosis	4.69e-05	0.00101	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	4.68e-05	0.001	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CNR1—multiple sclerosis	4.64e-05	0.000994	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GPR65—multiple sclerosis	4.58e-05	0.00098	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCR2—multiple sclerosis	4.57e-05	0.000978	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	4.49e-05	0.000962	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—POMC—multiple sclerosis	4.48e-05	0.00096	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CCL5—multiple sclerosis	4.43e-05	0.000949	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CCR5—multiple sclerosis	4.4e-05	0.000941	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CCL2—multiple sclerosis	4.38e-05	0.000939	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—IL2RA—multiple sclerosis	4.33e-05	0.000928	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCL10—multiple sclerosis	4.27e-05	0.000915	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CNR1—multiple sclerosis	4.21e-05	0.000902	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCR1—multiple sclerosis	4.19e-05	0.000896	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCL13—multiple sclerosis	4.19e-05	0.000896	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCL10—multiple sclerosis	4.18e-05	0.000895	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SRM—multiple sclerosis	4.06e-05	0.000869	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CCL5—multiple sclerosis	4.05e-05	0.000867	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCL3—multiple sclerosis	4.05e-05	0.000866	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CCR5—multiple sclerosis	3.99e-05	0.000855	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL2RA—multiple sclerosis	3.93e-05	0.000842	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PTGER4—multiple sclerosis	3.89e-05	0.000834	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	3.89e-05	0.000833	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PGR—multiple sclerosis	3.84e-05	0.000821	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCL10—multiple sclerosis	3.79e-05	0.000813	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCR3—multiple sclerosis	3.76e-05	0.000805	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.76e-05	0.000805	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CD28—multiple sclerosis	3.73e-05	0.000798	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCL5—multiple sclerosis	3.68e-05	0.000787	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCR2—multiple sclerosis	3.66e-05	0.000784	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CCR5—multiple sclerosis	3.65e-05	0.000781	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CCL5—multiple sclerosis	3.6e-05	0.00077	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—IL2RA—multiple sclerosis	3.6e-05	0.00077	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	3.45e-05	0.00074	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—POMC—multiple sclerosis	3.44e-05	0.000736	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CNR1—multiple sclerosis	3.38e-05	0.000723	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCL3—multiple sclerosis	3.36e-05	0.000719	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCR5—multiple sclerosis	3.31e-05	0.000709	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCL5—multiple sclerosis	3.27e-05	0.000699	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL2RA—multiple sclerosis	3.26e-05	0.000699	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CCR5—multiple sclerosis	3.24e-05	0.000694	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PTGER4—multiple sclerosis	3.23e-05	0.000692	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—IL2RA—multiple sclerosis	3.19e-05	0.000684	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PGR—multiple sclerosis	3.18e-05	0.000682	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCR3—multiple sclerosis	3.12e-05	0.000669	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—POMC—multiple sclerosis	3.12e-05	0.000668	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CD28—multiple sclerosis	3.09e-05	0.000662	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CCL2—multiple sclerosis	3.05e-05	0.000654	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCL10—multiple sclerosis	3.04e-05	0.000651	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCR2—multiple sclerosis	3.04e-05	0.00065	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCL3—multiple sclerosis	2.98e-05	0.000639	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCR5—multiple sclerosis	2.94e-05	0.00063	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL2RA—multiple sclerosis	2.9e-05	0.000621	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PTGER4—multiple sclerosis	2.87e-05	0.000615	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.86e-05	0.000612	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.86e-05	0.000612	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—POMC—multiple sclerosis	2.85e-05	0.000611	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PGR—multiple sclerosis	2.83e-05	0.000606	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CNR1—multiple sclerosis	2.8e-05	0.0006	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCR3—multiple sclerosis	2.77e-05	0.000594	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—TYK2—multiple sclerosis	2.77e-05	0.000594	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD28—multiple sclerosis	2.75e-05	0.000588	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCR2—multiple sclerosis	2.7e-05	0.000578	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CD86—multiple sclerosis	2.66e-05	0.000569	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCL5—multiple sclerosis	2.62e-05	0.00056	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.61e-05	0.00056	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—POMC—multiple sclerosis	2.59e-05	0.000554	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—IL2—multiple sclerosis	2.54e-05	0.000544	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CCL2—multiple sclerosis	2.53e-05	0.000543	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	2.53e-05	0.000542	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCL10—multiple sclerosis	2.52e-05	0.00054	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	2.49e-05	0.000533	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SPP1—multiple sclerosis	2.42e-05	0.000519	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCR5—multiple sclerosis	2.36e-05	0.000505	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL2RA—multiple sclerosis	2.32e-05	0.000498	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL2—multiple sclerosis	2.31e-05	0.000494	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—TYK2—multiple sclerosis	2.3e-05	0.000493	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	2.3e-05	0.000492	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	2.25e-05	0.000482	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	2.24e-05	0.00048	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CD86—multiple sclerosis	2.21e-05	0.000473	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCL5—multiple sclerosis	2.17e-05	0.000465	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.17e-05	0.000464	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APOE—multiple sclerosis	2.15e-05	0.000459	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—IL2—multiple sclerosis	2.11e-05	0.000451	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	2.04e-05	0.000438	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SPP1—multiple sclerosis	2.01e-05	0.000431	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	1.96e-05	0.00042	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCR5—multiple sclerosis	1.96e-05	0.000419	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CD80—multiple sclerosis	1.94e-05	0.000415	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	1.93e-05	0.000413	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2RA—multiple sclerosis	1.93e-05	0.000413	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL2—multiple sclerosis	1.91e-05	0.00041	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	1.87e-05	0.000401	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—POMC—multiple sclerosis	1.84e-05	0.000395	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCL2—multiple sclerosis	1.8e-05	0.000386	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	1.79e-05	0.000383	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APOE—multiple sclerosis	1.78e-05	0.000381	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—MAPK1—multiple sclerosis	1.76e-05	0.000378	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	1.74e-05	0.000372	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	1.71e-05	0.000367	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	1.7e-05	0.000364	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TYK2—multiple sclerosis	1.64e-05	0.000351	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CD80—multiple sclerosis	1.61e-05	0.000345	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	1.58e-05	0.000339	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	1.53e-05	0.000328	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	1.5e-05	0.00032	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.46e-05	0.000314	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	1.43e-05	0.000306	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL2—multiple sclerosis	1.36e-05	0.000292	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	1.36e-05	0.000291	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	1.36e-05	0.000291	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—multiple sclerosis	1.36e-05	0.00029	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	1.33e-05	0.000285	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.3e-05	0.000279	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP9—multiple sclerosis	1.29e-05	0.000276	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.24e-05	0.000267	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	1.21e-05	0.000258	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—STAT3—multiple sclerosis	1.15e-05	0.000245	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	1.13e-05	0.000242	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	1.13e-05	0.000241	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	1.07e-05	0.000229	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MYC—multiple sclerosis	1.07e-05	0.000228	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFB1—multiple sclerosis	1.06e-05	0.000228	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK1—multiple sclerosis	1.04e-05	0.000223	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	1e-05	0.000215	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	9.99e-06	0.000214	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	9.51e-06	0.000204	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	9.51e-06	0.000204	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	8.84e-06	0.000189	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	8.82e-06	0.000189	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	8.65e-06	0.000185	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	8.45e-06	0.000181	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—multiple sclerosis	8.01e-06	0.000171	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	7.85e-06	0.000168	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	7.83e-06	0.000168	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	7.68e-06	0.000165	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—APOE—multiple sclerosis	7.49e-06	0.00016	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	6.65e-06	0.000142	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—POMC—multiple sclerosis	6.43e-06	0.000138	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	5.9e-06	0.000126	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALB—multiple sclerosis	5.86e-06	0.000126	CbGpPWpGaD
